Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2015 (2015), Article ID 563820, 6 pages
http://dx.doi.org/10.1155/2015/563820
Review Article

Foetal Cell Transplantation for Parkinson’s Disease: Focus on Graft-Induced Dyskinesia

Department of Biomedical Sciences, Section of Physiology, Cagliari University, SS 554, km 4.500, 09042 Monserrato, Italy

Received 26 June 2015; Revised 2 December 2015; Accepted 16 December 2015

Academic Editor: Marjan Jahanshahi

Copyright © 2015 Elisabetta Tronci et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. R. Chaudhuri, D. G. Healy, and A. H. V. Schapira, “Non-motor symptoms of Parkinson's disease: diagnosis and management,” Review: Literature and Arts of the Americas, vol. 5, pp. 235–245, 2006. View at Publisher · View at Google Scholar
  2. E. O. Backlund, P. O. Granberg, B. Hamberger et al., “Transplantation of adrenal medullary tissue to striatum in parkinsonism. First clinical trials,” Journal of Neurosurgery, vol. 62, no. 2, pp. 169–173, 1985. View at Publisher · View at Google Scholar · View at Scopus
  3. O. Lindvall, E.-O. Backlund, L. Farde et al., “Transplantation in Parkinson's disease: two cases of adrenal medullary grafts to the putamen,” Annals of Neurology, vol. 22, no. 4, pp. 457–468, 1987. View at Publisher · View at Google Scholar · View at Scopus
  4. J. H. Kordower, T. B. Freeman, B. J. Snow et al., “Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease,” The New England Journal of Medicine, vol. 332, no. 17, pp. 1118–1124, 1995. View at Publisher · View at Google Scholar · View at Scopus
  5. I. Mendez, R. Sanchez-Pernaute, O. Cooper et al., “Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease,” Brain, vol. 128, no. 7, pp. 1498–1510, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. O. Lindvall, “Developing dopaminergic cell therapy for Parkinson's disease-give up or move forward?” Movement Disorders, vol. 28, no. 3, pp. 268–273, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Widner, J. Tetrud, S. Rehncrona et al., “Bilateral fetal mesencephalic grafting in two patients with Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP),” The New England Journal of Medicine, vol. 327, no. 22, pp. 1556–1563, 1992. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Brundin, O. Pogarell, P. Hagell et al., “Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease,” Brain, vol. 123, no. 7, pp. 1380–1390, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. C. R. Freed, R. E. Breeze, N. L. Rosenberg et al., “Transplantation of human fetal dopamine cells for Parkinson’s disease. Results at 1 year,” Archives of Neurology, vol. 47, no. 5, pp. 505–512, 1990. View at Publisher · View at Google Scholar
  10. G. L. Defer, C. Geny, F. Ricolfi et al., “Long-term outcome of unilaterally transplanted Parkinsonian patients. I. Clinical approach,” Brain, vol. 119, part 1, pp. 41–50, 1996. View at Google Scholar
  11. G. K. Wenning, P. Odin, P. Morrish et al., “Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease,” Annals of Neurology, vol. 42, no. 1, pp. 95–107, 1997. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Hagell, A. Schrag, P. Piccini, M. Jahanshahi, R. Brown, S. Rehncrona et al., “Sequential bilateral transplantation in Parkinson's disease: effects of the second graft,” Brain, vol. 122, part 6, pp. 1121–1132, 1999. View at Google Scholar
  13. P. Remy, Y. Samson, P. Hantraye et al., “Clinical correlates of [18F]fluorodopa uptake in five grafted parkinsonian patients,” Annals of Neurology, vol. 38, no. 4, pp. 580–588, 1995. View at Publisher · View at Google Scholar
  14. G. V. Sawle, P. M. Bloomfield, A. Björklund et al., “Transplantation of fetal dopamine neurons in Parkinson's disease: PET [18F]6-L-fluorodopa studies in two patients with putaminal implants,” Annals of Neurology, vol. 31, no. 2, pp. 166–173, 1992. View at Publisher · View at Google Scholar · View at Scopus
  15. Z. Kefalopoulou, M. Politis, P. Piccini et al., “Long-term clinical outcome of fetal cell transplantation for Parkinson disease. Two case reports,” JAMA Neurology, vol. 71, no. 1, pp. 83–87, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. P. J. Hallett, O. Cooper, D. Sadi, H. Robertson, I. Mendez, and O. Isacson, “Long-term health of dopaminergic neuron transplants in Parkinson’s disease patients,” Cell Reports, vol. 7, no. 6, pp. 1755–1761, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. I. Mendez, A. Vĩuela, A. Astradsson et al., “Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years,” Nature Medicine, vol. 14, no. 5, pp. 507–509, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. R. A. Hauser, T. B. Freeman, B. J. Snow et al., “Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease,” Archives of Neurology, vol. 56, no. 2, pp. 179–187, 1999. View at Publisher · View at Google Scholar · View at Scopus
  19. C. R. Freed, P. E. Greene, R. E. Breeze et al., “Transplantation of embryonic dopamine neurons for severe Parkinson's disease,” The New England Journal of Medicine, vol. 344, no. 10, pp. 710–719, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. C. W. Olanow, C. G. Goetz, J. H. Kordower et al., “A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease,” Annals of Neurology, vol. 54, no. 3, pp. 403–414, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. O. Lindvall and A. Björklund, “Cell therapy in Parkinson’s disease,” NeuroRx, vol. 1, no. 4, pp. 382–393, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Winkler, D. Kirik, and A. Björklund, “Cell transplantation in Parkinson's disease: how can we make it work?” Trends in Neurosciences, vol. 28, no. 2, pp. 86–92, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. P. Hagell, P. Piccini, A. Björklund et al., “Dyskinesias following neural transplantation in Parkinson's disease,” Nature Neuroscience, vol. 5, no. 7, pp. 627–628, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. Ma, C. Tang, T. Chaly et al., “Dopamine cell implantation in Parkinson's disease: long-term clinical and 18F-FDOPA PET outcomes,” Journal of Nuclear Medicine, vol. 51, pp. 7–15, 2010. View at Publisher · View at Google Scholar
  25. C. W. Olanow, J.-M. Gracies, C. G. Goetz et al., “Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in parkinson's disease: a double blind video-based analysis,” Movement Disorders, vol. 24, no. 3, pp. 336–343, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Herzog, O. Pogarell, M. O. Pinsker et al., “Deep brain stimulation in Parkinson's disease following fetal nigral transplantation,” Movement Disorders, vol. 23, no. 9, pp. 1293–1296, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. T. Carlsson, M. Carta, A. Muñoz et al., “Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration,” Brain, vol. 132, no. 2, pp. 319–335, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. T. Carlsson, C. Winkler, M. Lundblad, M. A. Cenci, A. Björklund, and D. Kirik, “Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia,” Neurobiology of Disease, vol. 21, no. 3, pp. 657–668, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. E. L. Lane, C. Winkler, P. Brundin, and M. A. Cenci, “The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat,” Neurobiology of Disease, vol. 22, no. 2, pp. 334–345, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. Y. Ma, A. Feigin, V. Dhawan et al., “Dyskinesia after fetal cell transplantation for parkinsonism: a PET study,” Annals of Neurology, vol. 52, no. 5, pp. 628–634, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. E. Maries, J. H. Kordower, Y. Chu et al., “Focal not widespread grafts induce novel dyskinetic behavior in parkinsonian rats,” Neurobiology of Disease, vol. 21, no. 1, pp. 165–180, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. K. Steece-Collier, K. E. Soderstrom, T. J. Collier, C. E. Sortwell, and E. Maries-Lad, “Effect of levodopa priming on dopamine neuron transplant efficacy and induction of abnormal involuntary movements in Parkinsonian rats,” The Journal of Comparative Neurology, vol. 515, no. 1, pp. 15–30, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. T. J. Collier, J. O'Malley, D. J. Rademacher et al., “Interrogating the aged striatum: robust survival of grafted dopamine neurons in aging rats produces inferior behavioral recovery and evidence of impaired integration,” Neurobiology of Disease, vol. 77, pp. 191–203, 2015. View at Publisher · View at Google Scholar
  34. E. L. Lane, P. Brundin, and M. A. Cenci, “Amphetamine-induced abnormal movements occur independently of both transplant- and host-derived serotonin innervation following neural grafting in a rat model of Parkinson's disease,” Neurobiology of Disease, vol. 35, no. 1, pp. 42–51, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. J. García, T. Carlsson, M. Döbrössy, G. Nikkhah, and C. Winkler, “Extent of pre-operative L-DOPA-induced dyskinesia predicts the severity of graft-induced dyskinesia after fetal dopamine cell transplantation,” Experimental Neurology, vol. 232, no. 2, pp. 270–279, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. E. L. Lane, “Potential cellular and regenerative approaches for the treatment of Parkinson's disease,” Journal of Neuropsychiatric Disease and Treatment, vol. 4, no. 5, pp. 835–845, 2008. View at Google Scholar
  37. K. E. Soderstrom, G. Meredith, T. B. Freeman et al., “The synaptic impact of the host immune response in a parkinsonian allograft rat model: influence on graft-derived aberrant behaviors,” Neurobiology of Disease, vol. 32, no. 2, pp. 229–242, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Politis, “Dyskinesias after neural transplantation in Parkinson's disease: what do we know and what is next?” BMC Medicine, vol. 8, article 80, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Politis, W. H. Oertel, K. Wu et al., “Graft-induced dyskinesias in Parkinson's disease: high striatal serotonin/dopamine transporter ratio,” Movement Disorders, vol. 26, no. 11, pp. 1997–2003, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Björklund, “Dopaminergic transplants in experimental parkinsonism: cellular mechanisms of graft-induced functional recovery,” Current Opinion in Neurobiology, vol. 2, no. 5, pp. 683–689, 1992. View at Publisher · View at Google Scholar
  41. A. Vinuela, P. J. Hallett, C. Reske-Nielsen et al., “Implanted reuptake-deficient or wild-type dopaminergic neurons improve on L-dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson's disease,” Brain, vol. 131, no. 12, pp. 3361–3379, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. T. Carlsson, M. Carta, C. Winkler, A. Björklund, and D. Kirik, “Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease,” The Journal of Neuroscience, vol. 27, no. 30, pp. 8011–8022, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. E. Shin, J. Garcia, C. Winkler, A. Björklund, and M. Carta, “Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease,” Neurobiology of Disease, vol. 47, no. 3, pp. 393–406, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. E. Shin, C. Lisci, E. Tronci et al., “The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation,” Neurobiology of Disease, vol. 62, pp. 233–240, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. G. A. Smith, A. Heuer, A. Klein, N.-N. Vinh, S. B. Dunnett, and E. L. Lane, “Amphetamine-induced dyskinesia in the transplanted hemi-parkinsonian mouse,” Journal of Parkinson's Disease, vol. 2, no. 2, pp. 107–113, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. E. Shin, E. Tronci, and M. Carta, “Role of serotonin neurons in L-DOPA- and graft-induced dyskinesia in a rat model of parkinson's disease,” Parkinson's Disease, vol. 2012, Article ID 370190, 5 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. J. García, T. Carlsson, M. Döbrössy, G. Nikkhah, and C. Winkler, “Impact of dopamine to serotonin cell ratio in transplants on behavioral recovery and L-DOPA-induced dyskinesia,” Neurobiology of Disease, vol. 43, no. 3, pp. 576–587, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. O. Lindvall and A. Björklund, “Cell therapeutics in Parkinson's disease,” Neurotherapeutics, vol. 8, no. 4, pp. 539–548, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. R. A. Barker and H. Widner, “Immune problems in central nervous system cell therapy,” NeuroRx, vol. 1, no. 4, pp. 472–481, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. J. H. Kordower, S. Styren, M. Clarke, S. T. DeKosky, C. W. Olanow, and T. B. Freeman, “Fetal grafting for Parkinson's disease: expression of immune markers in two patients with functional fetal nigral implants,” Cell Transplantation, vol. 6, no. 3, pp. 213–219, 1997. View at Publisher · View at Google Scholar
  51. A. L. Piquet, K. Venkiteswaran, N. I. Marupudi, M. Berk, and T. Subramanian, “The immunological challenges of cell transplantation for the treatment of Parkinson's disease,” Brain Research Bulletin, vol. 88, no. 4, pp. 320–331, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. J. L. Hudson, A. Hoffman, I. Strömberg, B. J. Hoffer, and J. W. Moorhead, “Allogeneic grafts of fetal dopamine neurons: behavioral indices of immunological interactions,” Neuroscience Letters, vol. 171, no. 1-2, pp. 32–36, 1994. View at Publisher · View at Google Scholar
  53. P. Piccini, “Factors affecting the clinical outcome after neural transplantation in Parkinson's disease,” Brain, vol. 128, no. 12, pp. 2977–2986, 2005. View at Publisher · View at Google Scholar
  54. J.-Y. Li, E. Englund, J. L. Holton et al., “Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation,” Nature Medicine, vol. 14, no. 5, pp. 501–503, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. J. H. Kordower, Y. Chu, R. A. Hauser, T. B. Freeman, and C. W. Olanow, “Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease,” Nature Medicine, vol. 14, no. 5, pp. 504–506, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. Y. Chu and J. H. Kordower, “Lewy body pathology in fetal grafts,” Annals of the New York Academy of Sciences, vol. 1184, pp. 55–67, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. F. Niccolini, C. Loane, and M. Politis, “Dyskinesias in Parkinson's disease: views from positron emission tomography studies,” European Journal of Neurology, vol. 21, no. 5, p. 694-e43, 2014. View at Publisher · View at Google Scholar · View at Scopus
  58. H. Sauer and P. Brundin, “Effects of cool storage on survival and function of intrastriatal ventral mesencephalic grafts,” Restorative Neurology and Neuroscience, vol. 2, no. 3, pp. 123–135, 1991. View at Google Scholar · View at Scopus
  59. S. Zhao, S. Maxwell, A. Jimenez-Beristain et al., “Generation of embryonic stem cells and transgenic mice expressing green fluorescence protein in midbrain dopaminergic neurons,” The European Journal of Neuroscience, vol. 19, no. 5, pp. 1133–1140, 2004. View at Publisher · View at Google Scholar · View at Scopus
  60. P. Hagell and M. A. Cenci, “Dyskinesias and dopamine cell replacement in Parkinson's disease: a clinical perspective,” Brain Research Bulletin, vol. 68, no. 1-2, pp. 4–15, 2005. View at Publisher · View at Google Scholar · View at Scopus
  61. W.-L. Kuan, R. Lin, P. Tyers, and R. A. Barker, “The importance of A9 dopaminergic neurons in mediating the functional benefits of fetal ventral mesencephalon transplants and levodopa-induced dyskinesias,” Neurobiology of Disease, vol. 25, no. 3, pp. 594–608, 2007. View at Publisher · View at Google Scholar · View at Scopus
  62. O. Isacson, L. M. Bjorklund, and J. M. Schumacher, “Toward full restoration of synaptic and terminal function of the dopaminergic system in Parkinson's disease by stem cells,” Annals of Neurology, vol. 53, supplement 3, pp. S135–S148, 2003. View at Publisher · View at Google Scholar · View at Scopus
  63. E. L. Lane, A. Björklund, S. B. Dunnett, and C. Winkler, “Neural grafting in Parkinson's disease: unraveling the mechanisms underlying graft-induced dyskinesia,” in Progress in Brain Research, vol. 184 of Recent Advances in Parkinson's Disease—Translational and Clinical Research, chapter 14, pp. 295–309, Elsevier, 2010. View at Publisher · View at Google Scholar
  64. M. Carta, T. Carlsson, D. Kirik, and A. Björklund, “Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats,” Brain, vol. 130, no. 7, pp. 1819–1833, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. M. Carta and E. Tronci, “Serotonin system implication in L-DOPA-induced dyskinesia: from animal models to clinical investigations,” Frontiers in Neurology, vol. 5, article 78, 2014. View at Publisher · View at Google Scholar · View at Scopus
  66. E. Tronci, C. Fidalgo, and M. Carta, Levodopa-Induced Dyskinesia in Parkinson's Disease, Springer, London, UK, 2014. View at Publisher · View at Google Scholar
  67. R. de la Fuente-Fernández, V. Sossi, Z. Huang et al., “Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias,” Brain, vol. 127, no. 12, pp. 2747–2754, 2004. View at Publisher · View at Google Scholar · View at Scopus
  68. M. Politis, K. Wu, C. Loane et al., “Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients,” The Journal of Clinical Investigation, vol. 124, no. 3, pp. 1340–1349, 2014. View at Publisher · View at Google Scholar · View at Scopus
  69. D. Rylander, M. Parent, S. S. O'Sullivan et al., “Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia,” Annals of Neurology, vol. 68, no. 5, pp. 619–628, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. Y. Takeuchi, T. Sawada, S. Blunt, P. Jenner, and C. D. Marsden, “Serotonergic sprouting in the neostriatum after intrastriatal transplantation of fetal ventral mesencephalon,” Brain Research, vol. 551, no. 1-2, pp. 171–177, 1991. View at Publisher · View at Google Scholar · View at Scopus
  71. A. K. Wright, G. W. Arbuthnott, and S. B. Dunnett, “Serotonin hyperinnervation after foetal nigra or raphe transplantation in the neostriatum of adult rats,” Neuroscience Letters, vol. 128, no. 2, pp. 281–284, 1991. View at Publisher · View at Google Scholar · View at Scopus
  72. A. S. Eison and D. L. Temple, “Buspirone: review of its pharmacology and current perspectives on its mechanism of action,” The American Journal of Medicine, vol. 80, supplement 2, no. 3, pp. 1–9, 1986. View at Publisher · View at Google Scholar
  73. H. J. Rijnders and J. L. Slangen, “The discriminative stimulus properties of buspirone involve dopamine-2 receptor antagonist activity,” Psychopharmacology, vol. 111, no. 1, pp. 55–61, 1993. View at Publisher · View at Google Scholar · View at Scopus